ENTPD1 and ischemic stroke: Given the demonstrated efficacy of anti-VCAM-CD39 in an ischemic stroke model [16], we hypothesised that anti-VCAM-CD39 would be able to protect the brain against global HIBI due to the known effects of suppression of inflammatory eATP and generation of protective adenosine in improving hypoxia induced endothelial damage [25].